A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML

Affiliations

• ¹ Department of Pathology, Microbiology and Immunology, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.
• ² Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
• ³ Hematopathology Service, Memorial Sloan Kettering Cancer Center, New York, NY.
• ⁴ Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
• ⁵ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
• ⁶ Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.
• ⁷ Celgene Corporation, Summit, NJ.
• ⁸ Agios Pharmaceuticals, Inc, Cambridge, MA.
• ⁹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.
• ¹⁰ Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and.
• ¹¹ Program in Cancer Biology and.
• ¹² Center for Immunobiology, Vanderbilt University School of Medicine, Nashville, TN.